Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader

Plus Russia Extends India Alliances

Executive Summary

After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.

You may also be interested in...



Initial $4.8bn Outlay To Back India's COVID-19 Vaccination Run

Significant allocations for public health programs and vaccination are prominent features of India's budget for fiscal 2021-22, though execution of these plans will be critical. Pharma is also keenly tracking a proposed allocation to bolster the overall research ecosystem and opening up of the insurance sector to foreign ownership.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

UK Grants First Worldwide Authorization For Pfizer/BioNTech COVID-19 Vaccine

The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel